Companies › IKT

INHIBIKASE THERAPEUTICS INC (IKT)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001750149 · EDGAR filings · Updated 2026-07-28

INHIBIKASE THERAPEUTICS INC (IKT) has reported institutional ownership of 86.3%, with 104 institutional managers holding positions valued at $191.5M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (2)

• 2026-07-28 — SCHEDULE 13G filed
• 2026-07-23 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-17 — Initial insider ownership filed (Form 3)
• 2026-07-17 — SCHEDULE 13G filed
• 2026-07-14 — Current report (8-K) filed
• 2026-06-30 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, INHIBIKASE THERAPEUTICS INC has 104 institutional holders and institutional ownership of 86.3%.

Insider activity

Insiders reported 5 transactions (1 buys, 0 sells) across 6 reporting insiders, with a net reported value of $3.00M.

Data flags from SEC filings

Related companies

OCUGEN INC COM (OCGN) · ATRIUM THERAPEUTICS INC (RNA) · CONTEXT THERAPEUTICS INC (CNTX) · ALECTOR INC (ALEC) · ALX ONCOLOGY HLDGS INC (ALXO) · EVOLUS INC (EOLS)